Technology

_____________________________________________

Watch the Slide Show Presented at the 2018 New York Oncology Investors Conference Sponsored by the National Foundation for Cancer Research

_____________________________________________

This slide show has animations, please use a left mouse click on the slide to index the animation. The arrows to the right and left of the “Slide” label at the bottom moves through the slides without showing the animation clearly.

TECHNOLOGY

OTraces’ technology focuses on in vitro diagnostic (IVD) predictive power enhancement, mainly using computational methods used in other fields such as deep space exploration to retrieve faint messages from distant spacecraft, as adapted to the requirements of disease detection. Success to date has been extraordinary thus far. Noise suppression techniques and spatial proximity correlations that orchestrate the action and interactions of biomarkers to achieve optimal results in both accuracy and access to the tumor microenvironment. No other competitive technologies are known to be pursuing this approach.

The principal omnibus patent (pending) filing, dated January 22, 2016 provides comprehensive patent protection for OTraces, Inc. for all known computational methods for achieving predictive power of 90%-plus and that apply to all types and classes of biomarkers and biomolecules, and specifically covers the following:

TECHNICAL ADVANCES INCORPORATED IN THE OTRACES PLATFORM

  • Incrementally improving correlation method predictive power, (several),
  • Using non protein based independent variables in a meta-variable approach,
  • Methods for extracting data using novel and non-traditional methods, and
  • Methods for “personalized” diagnosis based upon personalized “baseline” measurements.

Company management believes that the current IP portfolio of submissions constitutes “blocking patents”, some of which may be combined in the patent prosecution process but all concepts have been validated and will be included in the patents prosecuted through to issuance.

The company’s IP strategy is to continue to patent methods it discovers that will improve predictive power of the correlation methods used in the OTraces method.

PERFORMANCE TRACK RECORD

The OTraces method represents a cancer detection platform for a number of solid tumor cancers, as all solid tumors investigated with the OTraces method demonstrate high predictive power. The table below shows results for the five cancers investigated to date. The data from the Gertsen Clinical Laboratory in Moscow represents the third party clinical trial for market clearance in the Russian Federation, while the Johns Hopkins results are for prostate cancer test validation in the U.S.

Company management believes that the current IP portfolio of submissions constitutes “blocking patents”, some of which may be combined in the patent prosecution process but all concepts have been validated and will be included in the patents prosecuted through to issuance. The company’s IP strategy is to continue to patent methods it discovers that will improve predictive power of the correlation methods used in the OTraces method.

PROTEOMIC COMPLEXITY

A principal roadblock to diagnostic performance are various sources of disease “noise”– corruption from extraneous sources that conventional testing methods cannot resolve. In today’s chemistry-based assays, protein (or other biomolecule) concentration levels can be altered by scores of medical conditions in the population (or drugs routinely consumed by this population) that affect the up or down regulation of the biomarkers of choice. Furthermore, biological systems can exhibit complex non-linear behaviors that are very difficult to model in a correlation method.

The following table illustrates some of the non-cancer sources of “noise” as it pertains to human Interleukin-6, a widely used diagnostic protein that is part of the OTraces breast cancer screening panel.

Non-Cancer Medical Conditions/Administered Drugs
Up-regulated by Interleukin 6

Alcoholism Cardiomyopathy Rheumatoid Arthritis
Asthma COPD Schizophrenia
Autoimmune Disease Major Depressive Disorder Viral infections
Bacterial infections Pulmonary Hypertension Vaccines

Figure 1 from the OTraces’ breast cancer trial at the Gertsen Institute shows two important biomarkers used in the test, IL 6 and VEGF, sampled in 200 women who have been diagnosed either with breast cancer (red) or 200 who have been previously diagnosed as cancer-free (blue). This plot is typical of hundreds of others where non-cancer and cancer are poorly discriminated, and contaminated from unknowable information confounds the correlation of these concentrations to the disease transition.

Figure 2 shows the same biomarker measurements for the same 400 women employed in the Gertsen validation trials with the OTraces’ math-based methods, including patented noise-suppression and computational techniques, applied . This is not a full reflection of OTraces’ diagnostic capacity as only two of the five biomarkers (and thus only a fraction of the five-dimensional grid) were utilized.

EARLY DETECTION

Figure 3 traces biomarker levels in the Gertsen Institute validation trials for breast cancer, tracking them from healthy (-1 on the horizontal axis) through Stage 3, showing two noteworthy developments: (i) how quickly immune response takes place at early stage tumor formation; and (ii) how dramatically biomarkers surge during transition from healthy to Stage 0 tumors and most reach their highest levels at this stage —- further evidence of the accuracy enhancement potential of the OTraces technology: (iii) That this modality comprises a dynamic “motion picture” of tumor progression that is unique in cancer blood testing and an important advance in “liquid biopsy” that surpasses the known capabilities of DNA methods which are a virtual snapshot by comparison.

Figure 3, Action of Biomarkers by breast cancer stage

PROSTATE CANCER

Saving Costs by Reducing Unnecessary Biopsies and Saving Lives by Detecting Tumor Progression Before It is Too Late.

OTraces has completed one of three phases of third party blind validation of its prostate cancer test at Johns Hopkins Medical Center for the detection of aggressive PCa — an important unmet need in active surveillance patient monitoring as current A-S methods such as PSA often miss the progression from moderate to aggressive tumors until it is often too late to save the patient. Figure 4 below shows the resulting receiver operator curve (ROC) for the PSA test.

At a PSA level of 4 nano-gram/milliliter or higher in a man’s serum, the test achieves a false negative rate of 10%, 90% sensitivity, but gives up a 75% false positive rate (25% specificity). This means that the test misses 10 out 100 men with prostate cancer and 75% of those who measure positive for the PSA test get biopsies, though they do not have cancer.
In contrast OTraces test will only miss 5% of men with cancer. The false positive rate the test is only 11%, a far better outcome for men.